FDA

Clarity Receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in Biochemical Recurrence of Prostate Cancer

Clarity

FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

U.S. Food & Drug Administration

Sun Pharma Announces USFDA Approval of YONSA® (abiraterone acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With Methylprednisolone

Sun Pharma

Clinical Trial

ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Pharmaceutical Companies